At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ARMP Armata Pharmaceuticals, Inc.
Closed Good Friday 04-17 16:00:00 EDT
1.23
+0.05
+4.24%
盘后1.23
+0.000.00%
16:05 EDT
| High1.25 | Low1.20 | Vol7.03K |
| Open1.25 | D1 Closing1.18 | Amplitude4.16% |
| Mkt Cap44.51M | Tradable Cap13.57M | Total Shares36.18M |
| T/O8.68K | T/O Rate0.06% | Tradable Shares11.04M |
| P/B-0.93 | ROE-3439.35% | EPS-0.89 |
| 52wk High3.45 | 52wk Low0.8981 | P/E-1.38 |
| Dividend0.00 | Div.Yield0.00 | ROA-28.70% |
New Strong Sell Stocks for April 9th
Zacks · 04-09
Armata Pharmaceuticals Q4 2024 GAAP EPS $(0.23) Beats $(0.35) Estimate, Sales $1.24M Miss $1.56M Estimate
Benzinga · 03-20
BRIEF-Armata Pharmaceuticals Announces Fourth Quarter And Full-Year 2024 Results And Provides Corporate Update
Reuters · 03-20
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update
THOMSON REUTERS · 03-20
Armata Pharmaceuticals Enters $10 Million Secured Credit Agreement with Innoviva
MT Newswires Live · 03-13
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit
PR Newswire · 03-11
Armata Pharmaceuticals Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 2024-12-19
Armata Pharma’s inhaled AP-PA02 shows positive results in Phase 2 study
TIPRANKS · 2024-12-19
Armata Pharmaceuticals Announces Encouraging Results From the Phase 2 Tailwind Study of Inhaled AP-Pa02 in Non-Cystic Fibrosis Bronchiectasis Subjects With Chronic Pulmonary Pseudomonas Aeruginosa Infection
THOMSON REUTERS · 2024-12-19
Armata Pharmaceuticals Inc - One Possibly-Related Serious Adverse Event Linked to Acute Pulmonary Event
THOMSON REUTERS · 2024-12-19
Armata Pharmaceuticals Inc - Inhaled AP-Pa02 Well-Tolerated With Mild Adverse Events
THOMSON REUTERS · 2024-12-19
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
PR Newswire · 2024-12-19
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
BRIEF-Armata Pharmaceuticals Announces That CEO Dr. Deborah Birx Will Deliver A Presentation At The 5th Annual Phage Futures Annual Meeting
Reuters · 2024-11-19
Armata Pharmaceuticals Announces That CEO DR. Deborah Birx Will Deliver a Presentation at the 5TH Annual Phage Futures Annual Meeting
THOMSON REUTERS · 2024-11-19
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
PR Newswire · 2024-11-19
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
Armata Pharmaceuticals Q3 EPS $(0.15) Beats $(0.28) Estimate, Sales $2.97M Beat $900.00K Estimate
Benzinga · 2024-11-13
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update
PR Newswire · 2024-11-13
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update
Armata Pharmaceuticals Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 2024-11-12
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
PR Newswire · 2024-11-12
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
Armata Pharmaceuticals Announces Structural Biology Publication
PR Newswire · 2024-10-30
Armata Pharmaceuticals Announces Structural Biology Publication
Introduction
Company Name.
Armata Pharmaceuticals, Inc.
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App